Repurposing of FDA-approved drugs as novel therapeutics for COVID-19
- Funded by Canadian Institutes of Health Research (CIHR)
- Total publications:0 publications
Grant number: 170659
Grant search
Key facts
Disease
COVID-19Known Financial Commitments (USD)
$340,513.38Funder
Canadian Institutes of Health Research (CIHR)Principal Investigator
PendingResearch Location
CanadaLead Research Institution
CIUSSS de Centre-Ouest-de-l'Ile-de-Montréal-Jewish GeneralResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Currently, there is no vaccine or effective therapeutics for COVID-19, which is caused by 2019-nCoV (now officially referred to as SARS-CoV-2). Tens of thousands of people get infected by SARS-CoV-2 and substantial percentage of them showed severe symptoms. Dr Wu's team proposed to rapidly screen database of FDA-approved drugs by computationally approaches and further evaluate the top-ranking candidates by an array of experimental assays. This project could rapidly lead to drug candidates for COVID-19.